Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LESSINA-28 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Levonorgestrel: primarily CYP3A4, with reduction and conjugation to sulfate and glucuronide metabolites. Ethinyl estradiol: primarily CYP3A4, undergoes hydroxylation and conjugation to sulfate and glucuronides.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Levonorgestrel: 97-99% bound to albumin and SHBG; ethinyl estradiol: 98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Levonorgestrel: 1.8 L/kg; ethinyl estradiol: 2.3 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: approximately 90% for levonorgestrel; approximately 45% for ethinyl estradiol (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential for fluid retention; consider alternative contraception.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute liver disease or severe cirrhosis (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), no dose adjustment; use with caution and monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults (one tablet daily) with monitoring for bone mineral density and thrombotic risk.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. In perimenopausal women, same dosing as adults; discontinue at menopause due to increased risk of thrombosis and cardiovascular events.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Risk increases with age and number of cigarettes smoked (especially in women >35 years). Women who use COCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Smoking and cardiovascular risk,Increased risk of thromboembolic events (venous and arterial),Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid metabolic effects,Headache exacerbation,Bleeding irregularities,Pregnancy and hepatic enzyme induction,Ocular lesions (eg, retinal thrombosis)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Current or history of breast cancer or other estrogen/progestin-sensitive neoplasia,Hepatic adenoma or carcinoma,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Active liver disease or impaired liver function,Hypersensitivity to any component,Use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific dietary restrictions. Grapefruit juice may increase estrogen levels; avoid large quantities. Maintain a consistent intake of caffeine as it can be metabolized more slowly, possibly causing jitteriness.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: No increased risk of major birth defects based on large cohort studies. Second and third trimesters: Associated with increased risk of intrauterine growth restriction (IUGR), preterm birth, and transient neonatal hepatotoxicity (elevated liver enzymes) with prolonged use.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Minimal excretion into breast milk; M/P ratio approx 0.1–0.3. Considered compatible with breastfeeding by AAP; monitor infant for diarrhea or rash.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. Use caution in cholestasis or hepatic impairment.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Lessina-28 is a combined oral contraceptive containing ethinyl estradiol and levonorgestrel. Administer at the same time daily to maintain consistent hormone levels and maximize contraceptive efficacy. Use of additional non-hormonal contraception is recommended during the first 7 days of therapy. Missed pills increase breakthrough bleeding and pregnancy risk; consult package insert for missed dose instructions. Drug interactions with rifampin, certain anticonvulsants (e.g., phenytoin, carbamazepine), and St. John's wort may reduce contraceptive effectiveness.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time; if you miss a pill, follow the instructions in the package insert.,Lessina-28 does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding; these often improve after a few cycles.,Report severe headaches, vision changes, leg pain or swelling, chest pain, or jaundice to your healthcare provider immediately.,Do not smoke while using this medication; smoking increases risk of serious cardiovascular events, especially in women over 35.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LESSINA-28 vs AFIRMELLE, answered by our medical review team.
LESSINA-28 is a Oral Contraceptive that works by Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LESSINA-28 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LESSINA-28 is: One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LESSINA-28 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LESSINA-28 is classified as Category C. First trimester: No increased risk of major birth defects based on large cohort studies. Second and third trimesters: Associated with increased risk of intrauterine growth restrict. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.